first
case
atyp
pneumonia
appear
fosham
guangdong
provinc
china
novemb
februari
case
sever
acut
respiratori
syndrom
sar
report
guangdong
provinc
china
contain
public
health
isol
quarantin
measur
epidem
spread
countri
contin
affect
peopl
sar
infect
caus
respiratori
diseas
organ
system
includ
gastrointestin
tract
also
sever
affect
elderli
immunocompromis
sever
affect
suffer
greater
morbid
mortal
juli
death
attribut
infect
viru
base
serolog
data
sampl
collect
prior
outbreak
retrospect
analyz
individu
work
anim
trade
seroposit
histori
ill
indic
sar
may
either
extrem
mild
asymptomat
case
sever
acut
respiratori
syndrom
viru
sarscov
envelop
rna
viru
member
coronavirida
famili
also
includ
human
pathogen
typic
caus
mild
upper
respiratori
infect
coronavirus
envelop
virus
positivesens
singlestrand
rna
genom
sarscoronaviru
sarscov
unknown
prior
outbreak
diseas
may
mutant
human
coronaviru
acquir
new
virul
factor
allow
infect
human
popul
genom
rna
encas
nucleocapsid
n
protein
surround
lipid
membran
contain
spike
glycoprotein
membran
glycoprotein
envelop
e
protein
oligom
sglycoprotein
form
characterist
spike
protrud
membran
viral
entri
host
target
cell
appear
mediat
sarscov
spike
glycoprotein
depend
angiotensinconvert
enzym
function
receptor
addit
respons
attach
cellular
receptor
contain
epitop
viral
neutral
tcell
respons
studi
perform
vrc
investig
colleagu
shown
import
sglycoprotein
coronaviru
assembl
traffick
studi
demonstr
neutral
pseudovirion
express
protein
serum
convalesc
sar
patient
abil
dna
plasmid
vaccin
describ
induc
protect
immun
elicit
cellular
humor
immun
sarscov
anim
model
includ
gener
neutral
antibodi
nab
measur
plaquereduct
assay
studi
perform
beij
china
serum
patient
sar
use
neutral
assay
pseudotyp
lentivir
vector
bear
protein
indic
nab
first
detect
day
onset
symptom
peak
day
sustain
day
natur
spread
sever
ill
prompt
widespread
attempt
identifi
understand
diseas
caus
sar
determin
novel
coronaviru
viru
fulli
sequenc
may
rapid
identif
sequenc
viru
allow
scientist
begin
develop
candid
vaccin
quickli
current
licens
human
sar
vaccin
one
vaccin
clinic
trial
report
evalu
wholeinactiv
sar
vaccin
candid
develop
sinovac
biotech
co
ltd
china
current
report
describ
result
candid
sar
dna
vaccin
evalu
phase
clinic
trial
healthi
adult
initi
within
month
sequenc
viru
initi
publish
vrc
protocol
phase
openlabel
studi
safeti
toler
immunogen
sar
recombin
plasmid
dna
vaccin
encod
sar
spike
glycoprotein
healthi
adult
subject
singlesit
studi
conduct
vaccin
research
center
vrc
nation
institut
allergi
infecti
diseas
niaid
nation
institut
health
nih
bethesda
maryland
experiment
guidelin
us
depart
health
human
servic
follow
conduct
clinic
research
protocol
approv
niaid
institut
review
board
ten
subject
age
enrol
studi
decemb
may
three
inject
vaccin
dose
mg
administ
studi
day
mg
dose
later
deltoid
muscl
via
biojector
needlefre
inject
manag
system
tm
dose
rout
studi
trial
base
preclin
data
data
clinic
trial
vrc
dna
vaccin
pathogen
subject
safeti
monitor
evalu
laboratori
clinic
find
advers
reaction
studi
visit
advers
event
code
medic
dictionari
regulatori
activ
meddra
solicit
symptom
local
system
reactogen
includ
pain
red
swell
myalgia
malais
headach
chill
nausea
temperatur
collect
subject
self
report
diari
card
follow
vaccin
subject
follow
total
week
studi
visit
complet
decemb
vaccin
compos
singl
close
circular
plasmid
dna
macromolecul
produc
bacteri
cell
cultur
contain
kanamycin
select
medium
bacteri
cell
growth
depend
upon
express
kanamycin
resist
protein
encod
portion
plasmid
dna
follow
growth
bacteri
cell
harbor
plasmid
plasmid
dna
purifi
vaccin
contain
cellular
viral
compon
plasmid
encod
singl
protein
clone
express
vector
cmvr
previous
describ
evalu
clinic
trial
candid
hiv
ebola
dna
vaccin
plasmid
construct
produc
delet
mutant
sar
spike
glycoprotein
urbani
strain
genbank
cytoplasm
domain
truncat
cd
vaccin
base
upon
cdna
express
sar
spike
glycoprotein
urbani
strain
codonmodif
optim
express
human
cell
express
full
sequenc
except
delet
last
coohtermin
amino
acid
vaccin
clinic
trial
prepar
current
good
manufactur
practic
cgmp
condit
vical
inc
la
jolla
ca
vaccin
met
lot
releas
specif
prior
administr
dna
vaccin
manufactur
mgml
concentr
phosphatebuff
salin
pb
vrc
plasmid
express
cell
purifi
major
protein
product
duplic
well
serial
dilut
volunt
sera
incub
h
c
sar
spike
antigencoatedblock
plate
follow
biotinconjug
antibodi
min
room
temperatur
streptavidinehorseradish
peroxidas
min
room
temperatur
tetramethylbenzidin
tmb
substrat
min
room
temperatur
color
develop
stop
addit
sulfur
acid
plate
read
within
min
nm
molecular
devic
spectramax
elisa
plate
reader
sunnyval
ca
mean
optic
densiti
od
dilut
correct
mean
od
dilut
preimmun
sampl
endpoint
titer
volunt
establish
last
dilut
preimmun
correct
od
subject
sampl
assess
presenc
vaccineinduc
neutral
antibodi
two
assay
first
luciferas
report
pseudotyp
lentiviralbas
assay
serial
dilut
sera
incub
base
luciferas
report
viru
particl
express
sar
spike
glycoprotein
produc
cell
previous
describ
target
cell
human
renal
adenocarcinoma
cell
line
obtain
atcc
inhibitori
concentr
ic
report
reciproc
dilut
analysi
perform
use
previous
describ
method
secondli
twofold
dilut
heatinactiv
serum
assay
quadrupl
well
plate
use
start
dilut
microneutr
assay
measur
antibodi
neutral
infect
tcid
sarscov
vero
cell
monolay
presenc
viral
cytopath
effect
read
day
dilut
serum
complet
prevent
cytopath
effect
well
calcul
reedmuench
formula
elispot
perform
subject
sampl
baselin
week
previous
describ
cell
stimul
overnight
vaccin
insert
specif
peptid
pool
cell
per
well
result
express
mean
spotform
cell
sfc
per
million
pbmc
tcell
respons
measur
ic
baselin
week
previous
describ
cell
stimul
vaccin
insert
specif
peptid
pool
cell
permeabil
wash
stain
directli
conjug
antihuman
antibodi
assess
express
facscalibur
flow
cytomet
bdi
assay
treat
binari
respondersnonrespond
use
usual
central
exact
confid
interv
binomi
rate
confid
true
respons
rate
antibodi
assay
larger
lower
limit
calcul
done
r
version
posit
tcell
respons
ic
elispot
data
base
composit
criteria
previous
describ
four
publish
studi
candid
vaccin
sa
version
sa
institut
splu
version
insight
use
analys
ten
healthi
adult
subject
age
year
mean
age
enrol
studi
subject
popul
consist
male
predominantli
white
nonhispaniclatino
subject
mean
bmi
rang
subject
educ
level
colleg
higher
advanc
degre
demograph
data
regard
subject
gender
age
raceethn
bodi
mass
index
bmi
educ
level
time
enrol
shown
tabl
data
collect
subject
diari
card
show
subject
experienc
least
one
mild
inject
site
symptom
fol
low
vaccin
paintend
swell
red
paintend
inject
site
common
complaint
five
ten
subject
report
least
one
mild
system
symptom
myalgia
malais
headach
chill
fever
follow
vaccin
among
solicit
symptom
none
subject
report
nausea
none
subject
report
moder
sever
symptom
follow
vaccin
tabl
subject
follow
week
safeti
immun
respons
nine
subject
complet
dose
vaccin
schedul
one
subject
subject
g
receiv
oral
glucocorticoid
treat
poison
ivi
contact
dermat
second
vaccin
maximum
local
system
b
reactogen
local
inject
site
reaction
record
clinician
min
postinject
record
selfassess
home
subject
diari
card
system
reaction
record
selfassess
home
subject
diari
card
follow
inject
report
sever
local
symptom
follow
vaccin
report
sever
system
symptom
follow
vaccin
b
consequ
withdrawn
vaccin
schedul
seriou
advers
event
grade
sever
lifethreaten
advers
event
overal
studi
vaccin
well
toler
found
safe
healthi
subject
age
year
sar
spike
glycoprotein
specif
antibodi
detect
elisa
subject
one
timepoint
tabl
neutral
detect
microneutr
plaqu
tabl
sar
specif
antibodi
titer
assess
elisa
week
week
week
week
nd
nd
b
nd
nd
c
e
f
g
h
j
done
nd
subject
neg
elisa
week
elisa
perform
timepoint
subject
g
receiv
vaccin
reduct
assay
sar
specif
neutral
antibodi
assess
pseudotyp
lentivir
vector
report
neutral
assay
detect
subject
one
timepoint
fig
neutral
antibodi
respons
peak
week
subject
remain
posit
week
pseudoviru
neutral
assay
highli
sensit
possibl
reason
discrep
result
two
neutral
assay
sar
spike
glycoprotein
specif
tcell
respons
induc
vaccin
assess
ic
elispot
tcell
respons
sar
cov
spike
antigen
detect
ic
subject
week
tcell
respons
detect
subject
tcell
respons
greater
frequenc
magnitud
respons
fig
tcell
respons
assess
elispot
detect
subject
cours
trial
posit
week
week
dose
vaccin
peak
tcell
respons
occur
week
present
sustain
throughout
trial
sar
repres
recent
emerg
infecti
diseas
caus
sever
ill
global
panic
econom
disrupt
rapid
respons
sar
outbreak
defin
quintessenti
respons
public
health
biomed
commun
newli
emerg
infecti
diseas
abil
quickli
identifi
describ
character
develop
countermeasur
includ
vaccin
futur
emerg
infecti
pathogen
critic
maintain
public
health
econom
stabil
global
respons
sar
epidem
provid
insight
educ
public
health
expert
scientist
util
optim
respond
futur
emerg
infect
includ
virus
avian
influenza
respons
sar
infect
sever
laboratori
rapidli
develop
vaccin
candid
includ
sar
candid
dna
vaccin
describ
report
preclin
evalu
safeti
demonstr
efficaci
lethal
murin
challeng
model
phase
human
trial
report
initi
within
month
similar
candid
dna
vaccin
hiv
ebola
viru
west
nile
viru
wnv
previous
evalu
safe
shown
elicit
vaccineinduc
cellular
humor
immun
respons
includ
neutral
antibodi
respons
wnv
vaccin
like
previous
evalu
vrc
dna
vaccin
sar
vaccin
induc
vaccinespecif
tcell
antibodi
respons
includ
neutral
antibodi
sar
spike
glycoprotein
sensit
pseudotyp
lentivir
report
assay
studi
sar
patient
antibodi
sar
cov
spike
membran
envelop
nucleocapsid
protein
present
assess
elisa
neutral
antibodi
elicit
spike
glycoprotein
openlabel
phase
clinic
trial
vrc
sar
dna
vaccin
evalu
safe
well
toler
vaccin
immunogen
sar
spike
glycoproteinspecif
tcell
respons
induc
subject
neutral
antibodi
respons
detect
subject
sar
spike
proteinspecif
cellular
respons
primarili
cell
minor
subject
detect
sar
spike
proteinspecif
tcell
respons
tcell
respons
import
effector
mechan
viral
clearanc
induct
popul
goal
genebas
vaccin
prior
vrc
clinic
trial
dna
vaccin
hiv
ebola
west
nile
viru
vaccinespecif
tcell
respons
detect
nearli
subject
frequenc
measur
tcell
respons
vari
aspect
dna
vaccineinduc
immun
requir
addit
develop
investig
inactiv
sar
vaccin
candid
develop
sinovac
biotech
co
ltd
found
immunogen
phase
studi
conduct
china
thirtysix
healthi
subject
receiv
dose
inactiv
sarscov
vaccin
either
sarscov
unit
placebo
control
vaccin
recipi
seroconvert
day
postvaccin
geometr
mean
titer
nab
measur
plaquereduct
format
peak
week
follow
second
immun
decreas
week
similar
kinet
observ
sar
dna
vaccin
subject
describ
report
vaccineinduc
cellular
immun
respons
report
studi
recov
sar
patient
demonstr
longliv
effectorcentr
memori
tcell
respons
sar
sprotein
well
sar
viral
protein
cell
thought
play
import
role
sar
immun
safeti
data
immun
respons
along
data
previous
report
trial
evalu
similar
dna
vaccin
pathogen
includ
ebola
wnv
hiv
indic
sar
dna
vaccin
consid
expand
clinic
evalu
potenti
futur
sar
outbreak
alon
primeboost
combin
vector
sar
dna
vaccin
induc
neutral
antibodi
strongli
associ
recoveri
natur
sar
infect
well
cellular
immun
respons
may
import
compon
sar
immun
neutral
activ
detect
sensit
pseudotyp
lentivir
assay
less
sensit
microneutr
plaquereduct
assay
sar
cov
contain
care
surveil
public
health
measur
licensur
vaccin
like
requir
use
anim
rule
model
reflect
pathogenesi
human
identif
valid
immun
correl
vaccin
also
demonstr
feasibl
rapid
manufactur
regulatori
review
provid
addit
safeti
immunogen
data
support
concept
dna
vaccin
potenti
vaccin
platform
futur
emerg
infecti
diseas
